Eider

Eider Biologics is a South Korean biotechnology company specializing in the development of next-generation protein therapeutics with extended half-lives and enhanced efficacy. The company utilizes its proprietary Eider-Long platform to create long-acting versions of existing biologics and its Eider-Body platform for the design of multi-specific antibodies. Its primary focus areas include ophthalmology, specifically targeting wet age-related macular degeneration (wAMD), and oncology. Eider Biologics aims to reduce the frequency of injections for patients with chronic diseases while maintaining therapeutic potency. The company's lead candidate, EB-101, is a long-acting VEGF inhibitor designed to provide superior durability compared to current standards of care. By optimizing the pharmacokinetic properties of biologics, Eider seeks to improve patient compliance and clinical outcomes in high-need therapeutic areas.